Company Summary - Phytopharm PLC (LSE:PYM)
8.55p
0.00p
FTSE Fledgling Pharmaceuticals & BiotechnologyMarket cap: £29.652m
NEW Explore our new and improved report for Phytopharm PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need
| Financials - Annual Report (30/09/2011) | ||
|---|---|---|
| Turnover | £m | 0.07 |
| Pre-tax Profit | £m | -8.17 |
| EPS | p | -2.21 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Alistair Taylor | Chairman |
| Tim Sharpington | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
ALS; Cogane(TM); Glaucoma; Hoodia; Myogane(TM); P61; Phytopica(R)
Subsidiaries
Phytotech Ltd
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Annual Information Update | 06/02/2012 |
| Directorate Change | 02/02/2012 |
| Annual Financial Report | 27/01/2012 |
For more information
and investor relations, visit the
Phytopharm PLC company website: